Patents by Inventor Martin J. Page

Martin J. Page has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080279852
    Abstract: The present invention relates to methods of treating a human patient suffering from rheumatoid arthritis, comprising: obtaining a CHO cell comprising antibody heavy and light chain genes which are constituted of cDNA and in a form that enables balanced expression of the light and heavy chains of a human or humanized recombinant antibody; culturing the CHO cell in a serum-free media; purifying the resulting recombinant antibody; and administering a therapeutically effective amount of the antibody expressed and glycosylated in a CHO cell expression system to said human patient.
    Type: Application
    Filed: July 28, 2008
    Publication date: November 13, 2008
    Inventors: Martin J. Page, James S. Crowe, Nicholas T. Rapson, Michael J. Keen
  • Publication number: 20040228857
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Application
    Filed: January 28, 2004
    Publication date: November 18, 2004
    Applicant: Glaxo Wellcome, Inc.
    Inventors: Martin J. Page, James S. Crowe
  • Publication number: 20030035799
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Application
    Filed: May 16, 2002
    Publication date: February 20, 2003
    Applicant: Glaxo Wellcome Inc.
    Inventors: Martin J. Page, James S. Crowe, Nicholas T. Rapson, Michael J. Keen
  • Publication number: 20020182208
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Application
    Filed: May 16, 2002
    Publication date: December 5, 2002
    Applicant: Glaxo Wellcome, Inc.
    Inventors: Martin J. Page, James S. Crowe
  • Patent number: 5545405
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: August 13, 1996
    Assignee: Burroughs Wellcome Co.
    Inventor: Martin J. Page
  • Patent number: 5545404
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: August 13, 1996
    Assignee: Burroughs Wellcome Co.
    Inventor: Martin J. Page
  • Patent number: 5545403
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: August 13, 1996
    Assignee: Burroughs Wellcome Co.
    Inventor: Martin J. Page
  • Patent number: 5322774
    Abstract: A process for the preparation of a protein, which process comprises culturing under such conditions that the protein is obtained cells infected with a recombinant baculovirus having a promoter, capable of directing the expression of a gene in the cells, operably linked to a heterologous gene which encodes the protein and which is preceded by a leader sequence comprising: T A A T C A T C C A C A G G A G A C T T T C T G [SEQ. ID NO: 1].
    Type: Grant
    Filed: October 23, 1991
    Date of Patent: June 21, 1994
    Assignee: Burroughs Wellcome Co.
    Inventors: Timothy C. Peakman, Martin J. Page, Ian G. Charles
  • Patent number: 5147788
    Abstract: A baculovirus transfer vector incorporates a restriction site into which a foreign gene may be cloned a short distance downstream of the N-terminus of the polyhedrin gene body and the natural ATG translation start codon for the polyhedrin gene is not provided such that the N-terminal polyhedrin coding sequence prior to the restriction site is retained but not capable of being translated.
    Type: Grant
    Filed: December 3, 1990
    Date of Patent: September 15, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Martin J. Page, Brian C. Rodgers